Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Rheumatology"
DOI: 10.1007/s10067-017-3584-y
Abstract: Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for… read more here.
Keywords: agent; kobio registry; time; biologic agent ... See more keywords
Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13199
Abstract: To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor (TNFi). read more here.
Keywords: agent rheumatoid; line biologic; rheumatoid arthritis; tumor necrosis ... See more keywords
Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Dermatology"
DOI: 10.1111/ijd.15560
Abstract: frequent, although there are very few published cases with lesions outside the skin and, to the best of our knowledge, none with glottic xanthogranulomas. However, exact diagnosis is difficult, and our case is a good… read more here.
Keywords: real world; line; treatment; biologic agent ... See more keywords